Under the terms of a supply agreement, Merck will manufacture and supply the alendronate sodium tablets to Watson, which will market, sell and distribute the product in the US. Merck will receive a share of the profits from Watson’s sales of the generic product in the US market.
Alendronate sodium is the generic version of Merck’s Fosamax tablets, indicated for the treatment of osteoporosis in postmenopausal women. Alendronate sodium is also indicated to increase bone mass in men with osteoporosis.